News

FDA Approves Folate-Containing Oral Contraceptive


 

From a Food and Drug Administration Announcement

The Food and Drug Administration on Sept. 24 approved Beyaz, a combined oral contraceptive that contains a folate.

Levomefolate calcium is a folic acid metabolite, a B vitamin “that helps produce and maintain new cells in the body,” according to an FDA announcement. Low folate levels in women of child-bearing age have been associated with neural tube defects, such as spina bifida.

Therefore, current recommendations suggest that all women of child-bearing age take supplemental folate.

Beyaz, manufactured by Bayer HealthCare Pharmaceuticals Inc., is based on the previously approved oral contraceptive YAZ and contains the same doses of estrogen and progestin (ethinyl estradiol, 20 mcg; drospirenone, 3 mg). Beyaz also contains 0.451 mg of levomefolate calcium.

Beyaz shares YAZ's approved indications: pregnancy prevention, treatment of premenstrual dysphoric disorder symptoms in women who use OCs for contraception, and treatment of moderate acne in patients aged 14 years and older who have chosen to use an oral contraceptive for birth control. Beyaz is approved for the secondary indication of raising folate levels to reduce risk of neural tube defects in women who conceive while using the product or shortly after discontinuing it.

A multicenter, double-blind, randomized controlled trial of 379 women aged 18–40 years in the United States who received YAZ or Beyaz for 24 weeks showed that Beyaz increased folate levels. A German study showed that folate levels remained elevated for several weeks following discontinuation of the drug.

Previous YAZ clinical trials provided safety and efficacy data for contraception, premenstrual dysphoric disorder, and acne indications for Beyaz.

Side effects most often reported by users of combined oral contraceptives are irregular uterine bleeding, nausea, breast tenderness, and headache. Serious side effects include blood clots and liver disease. All oral contraceptive users, especially those older than age 35, should not smoke. Side effects of Beyaz are expected to be similar to those of YAZ.

Recommended Reading

Specific Fats in Diet Tied to Endometriosis Risk
MDedge Endocrinology
Side Effects Similar in Both DMPA Formulations
MDedge Endocrinology
FDA Panel Backs New Emergency Contraceptive
MDedge Endocrinology
Panel: Hypoactive Sexual Desire Disorder Drug Ineffective
MDedge Endocrinology
Nonobese PCOS Patients Also Need the OGTT
MDedge Endocrinology
Early Menopause Tied to Increased CVD Risk
MDedge Endocrinology
Aromatase Inhibitor Recommended for Subset of Breast Ca
MDedge Endocrinology
Estrogen May Mediate Brain Aneurysm Risk
MDedge Endocrinology
Micronized Progesterone Subdues Hot Flashes
MDedge Endocrinology
Low Testosterone Predicts Frailty in Older Men
MDedge Endocrinology